 Nabriva Therapeutics plc NBRV announced today that the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA has adopted a positive opinion recommending approval of XENLETA lefamulin for the treatment of community-acquired pneumonia CAP in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of CAP or when these have failed. The CHMP opinion will be reviewed by the European Commission EC, which has the authority to approve medicines for all 28 countries of the European Union, Norway, Iceland, and Liechtenstein. Todays announcement brings us one step closer to the first approval of a new class of antibiotics for patients with community-acquired pneumonia in Europe in almost 20 years, said Jennifer Schranz, MD, Chief Medical Officer of Nabriva. 